<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005251</url>
  </required_header>
  <id_info>
    <org_study_id>1133</org_study_id>
    <secondary_id>R01HL042467</secondary_id>
    <nct_id>NCT00005251</nct_id>
  </id_info>
  <brief_title>Genetic Analysis of Familial Hypertrophic Cardiomyopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <brief_summary>
    <textblock>
      To map the genetic defect responsible for familial hypertrophic cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Familial hypertrophic cardiomyopathy is a disease of heart muscle that is genetically
      transmitted as an autosomal dominant trait, with a high degree of penetrance. Affected
      individuals typically have asymmetric thickening of the interventricular septum often
      involving the adjacent left ventricular free wall. Histologically, myocardial cells are
      enlarged and muscle bundles are grossly disorganized, producing a whorled pattern. The
      physiologic consequence of this cardiomyopathy is diastolic dysfunction with impaired
      ventricular relaxation and elevated diastolic pressures in the heart and pulmonary
      vasculature. Patients can experience dyspnea, angina, palpitations, and syncope.
      Complications of the disease include atrial fibrillation, congestive heart failure,
      thromboembolism, and most importantly, sudden death.

      DESIGN NARRATIVE:

      The three kindreds studied included one in Iceland, one in the St. Lawrence region in Canada,
      and one in the Pittsburgh, Pennsylvania area. Pedigrees were established for the three
      kindreds. All family members were clinically evaluated by physical exam, electrocardiogram,
      and comprehensive M-mode and two-dimensional echocardiography. Lymphoblastoid cell lines were
      derived from all members of the three pedigrees. Restriction fragment length polymorphism
      analyses were used to identify a DNA probe that was linked to familial hypertrophic
      cardiomyopathy. Studies were conducted to determine if the familial hypertrophic
      cardiomyopathy locus was the same in all three kindreds and to identify the gene responsible.

      The study completion date listed in this record was obtained from the &quot;End Date&quot; entered in
      the Protocol Registration and Results System (PRS) record.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1990</start_date>
  <completion_date type="Actual">March 1995</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Myocardial Diseases</condition>
  <condition>Cardiomyopathy, Hypertrophic</condition>
  <eligibility>
    <criteria>
      <textblock>
        No eligibility criteria
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J Clin Invest. 1992 Nov;90(5):1666-71.</citation>
    <PMID>1430197</PMID>
  </reference>
  <reference>
    <citation>Watkins H, Seidman CE, MacRae C, Seidman JG, McKenna W. Progress in familial hypertrophic cardiomyopathy: molecular genetic analyses in the original family studied by Teare. Br Heart J. 1992 Jan;67(1):34-8. Review.</citation>
    <PMID>1739523</PMID>
  </reference>
  <reference>
    <citation>Seidman CE, Seidman JG. Mutations in cardiac myosin heavy chain genes cause familial hypertrophic cardiomyopathy. Mol Biol Med. 1991 Apr;8(2):159-66. Review.</citation>
    <PMID>1806760</PMID>
  </reference>
  <reference>
    <citation>Solomon SD, Jarcho JA, McKenna W, Geisterfer-Lowrance A, Germain R, Salerni R, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest. 1990 Sep;86(3):993-9.</citation>
    <PMID>1975599</PMID>
  </reference>
  <reference>
    <citation>Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990 Sep 7;62(5):999-1006.</citation>
    <PMID>1975517</PMID>
  </reference>
  <reference>
    <citation>Solomon SD, Geisterfer-Lowrance AA, Vosberg HP, Hiller G, Jarcho JA, Morton CC, McBride WO, Mitchell AL, Bale AE, McKenna WJ, et al. A locus for familial hypertrophic cardiomyopathy is closely linked to the cardiac myosin heavy chain genes, CRI-L436, and CRI-L329 on chromosome 14 at q11-q12. Am J Hum Genet. 1990 Sep;47(3):389-94.</citation>
    <PMID>1975475</PMID>
  </reference>
  <reference>
    <citation>Tanigawa G, Jarcho JA, Kass S, Solomon SD, Vosberg HP, Seidman JG, Seidman CE. A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene. Cell. 1990 Sep 7;62(5):991-8.</citation>
    <PMID>2144212</PMID>
  </reference>
  <reference>
    <citation>Knowlton KU, Rockman HA, Itani M, Vovan A, Seidman CE, Chien KR. Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium. J Clin Invest. 1995 Sep;96(3):1311-8.</citation>
    <PMID>7657806</PMID>
  </reference>
  <reference>
    <citation>Watkins H, MacRae C, Thierfelder L, Chou YH, Frenneaux M, McKenna W, Seidman JG, Seidman CE. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet. 1993 Apr;3(4):333-7.</citation>
    <PMID>7981753</PMID>
  </reference>
  <reference>
    <citation>Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, Seidman CE. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994 Jun 3;77(5):701-12.</citation>
    <PMID>8205619</PMID>
  </reference>
  <reference>
    <citation>Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S, Vecchio C, Shono H, Nakao S, Tanaka H, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994 Jan;93(1):280-5.</citation>
    <PMID>8282798</PMID>
  </reference>
  <reference>
    <citation>Watkins H, Thierfelder L, Anan R, Jarcho J, Matsumori A, McKenna W, Seidman JG, Seidman CE. Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. Am J Hum Genet. 1993 Dec;53(6):1180-5.</citation>
    <PMID>8250038</PMID>
  </reference>
  <reference>
    <citation>Solomon SD, Wolff S, Watkins H, Ridker PM, Come P, McKenna WJ, Seidman CE, Lee RT. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol. 1993 Aug;22(2):498-505.</citation>
    <PMID>8335820</PMID>
  </reference>
  <reference>
    <citation>Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992 Apr 23;326(17):1108-14.</citation>
    <PMID>1552912</PMID>
  </reference>
  <verification_date>June 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2000</study_first_submitted>
  <study_first_submitted_qc>May 25, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2000</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic, Familial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

